AstraZeneca Net Worth 2010-2022 | AZN

Interactive chart of historical net worth (market cap) for AstraZeneca (AZN) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. AstraZeneca net worth as of January 31, 2023 is $204.08B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.078B $37.417B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $423.546B 15.94
Eli Lilly (LLY) United States $323.536B 40.83
Novo Nordisk (NVO) Denmark $314.688B 41.26
Merck (MRK) United States $268.980B 13.85
AbbVie (ABBV) United States $257.579B 10.68
Pfizer (PFE) United States $244.460B 6.68
Novartis AG (NVS) Switzerland $198.337B 14.94